Infertility Clinical Trial
Official title:
Assessing the Relation Between Hormone Receptors Gene Polymorphism and Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program
The aim of this study is to assess the role of AMH in prediction of poor ovarian response as well as the relation between ESR2 (+1730G>A) (rs4986938), FSHR p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs and the poor response in Egyptian women undergoing IVF procedure. Discovering the genetic variants associated with ovarian response is an important step towards individualized pharmacogenetic protocols of ovarian stimulation.
In-vitro fertilization treatment safety is highly challenged by the erratic individual
variability to controlled ovarian hyperstimulation (COH). One of the diverse predictive
factors is the AMH, which is considered to be the most sensitive marker. Nowadays, practices
of pharmacogenetics could predict the stimulation success and thus tailoring the treatment
reaching advancement in patient care. Since the efficiency of the Follicle stimulating
hormone (FSH) dose is greatly related to the success of COH, the FSHR gene is treated as the
primary candidate in explaining the difference in COH results.Furthermore, the estrogen
receptors are important genes for improvements in the diagnosis and treatment of
infertility.
Materials and Methods: Starting June 2013, couples with unexplained infertility, seeking the
first attempt IVF/ICSI treatment cycle will be recruited in "AL shark Al-Awsat fertility
center".In this prospective study, 216 Couples fulfilling our inclusion criteria will enroll
in this study after informed consent. Ovarian stimulation will be performed according to the
GnRH antagonist protocol with a fixed daily morning dose of Human menopausal gonadotrophin
(HMG) [Merional® 75 IU ampoules, IBSA institut] intra-muscular injection starting on cycle
day 2. Based on the patient's body mass index and hormonal profile, the daily dose of HMG
will be adjusted to (225 IU) for participants with AMH levels > 1.5 ng/ml and/or FSH levels
≤ 8 mIU/ml and to (300 IU) for participants with AMH levels < 1.5 ng/ml and/or FSH levels >
8 mIU/ml, doses will be increased by 75 IU in cases with BMI > 30 Kg/m2. On day 2 of the
menstrual cycle, the dose of HMG will be commenced for all patients and will be maintained
for 9-11 days according to each participant individual ovarian response assessed by
trans-vaginal ultrasound folliculometry starting on cycle day 7 and continued every other
day until the day of Human chorionic gonadotrophin (hCG) injection. On cycle day 7, the GnRH
antagonist Cetrorelix 0.25 mg [Cetrotide® 0.25 mg syringes, Merck Serono] will be introduced
as daily subcutaneous injections and continued till the day of ovulation triggering.
Finally, when at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered
by a single intra-muscular injection of 10,000 IU of hCG [Choriomon® 5000 IU ampoules, IBSA
institut]. 36 hours later, oocyte retrieval will be performed and will be guided by
transvaginal ultrasound. According to our primary outcome, the number of oocytes collected,
patients will be classified as poor responders (4 oocytes or less) and will be considered as
good responders if they produced 5 or more oocytes. The good responders group will serve as
the control group.
Genotyping:Peripheral blood will be collected from each patient in an EDTA-containing tube.
Genomic DNA will be extracted from lymphocytes of peripheral blood by fully automated system
of QIAcube using QIAamp DNA Blood Mini Kit (250) plus QIAamp DNA Blood Mini Accessory Set B,
cat. no. 1043369. Detection of the polymorphisms ESR2 (+1730G>A) (rs4986938), FSHR
p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs will be
performed using the TaqMan system by real-time polymerase chain reaction (PCR). Primers and
probes will be provided by applied biosystem, Life Technologies. Assays will be performed
with TaqMan Universal Master Mix.
Statistical analysis: Data will be statistically described in terms of mean and standard
deviation, for quantitative data and frequencies (number of cases) and relative frequencies
(percentages) for qualitative data. Hardy-Weinberg (H-W) Equilibrium for each polymorphism
will be tested using the Chi-square test. Comparison of quantitative variables will be done
using unpaired t test when comparing 2 categories and one way analysis of variance (ANOVA)
with post hoc test when comparing more than 2 categories.
For comparing categorical data, Chi square test will be performed. Exact test will be used
instead when the expected frequency is less than 5.
Genotype and allele frequencies will be compared between the disease and the control groups
using chi-square tests. Odds ratio (OR) with 95% confidence intervals will be calculated. A
probability value (P value) less than 0.05 will be considered statistically significant. All
statistical calculations will be done using SPSS (Statistical Package for the Social
Science; SPSS Inc., Chicago, IL, USA) version 22.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A |